Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Poster
  • Published:

Rational combination of cancer therapies with PD1 axis blockade

Nature Reviews Cancer (2024)Cite this article

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Immune checkpoint blockade (ICB) of the PD1–PDL1 interaction to promote anti-tumour immunity shows remarkable clinical benefit in some patients with cancer but the efficacy of single-agent therapy is limited by mechanisms within the tumour microenvironment that curtail effective immune responses. This poster from Nature Reviews Cancer and Nature Reviews Immunology illustrates approaches in four main categories — targeting effector T cells, innate immune and regulatory cells, the tumour microenvironment and stromal cells, and cancer cells — that could be combined with PD1 axis blockade to provide cooperative or synergistic clinical benefit. Given the large number of potential treatment combinations, it is crucial that therapies should be combined in a rational manner based on our mechanistic understanding of cancer–immune interactions.

This poster is freely available online thanks to support from STEMCELL Technologies.

The poster has been peer reviewed and, as always, Springer Nature retains sole responsibility for all editorial content.

Change history

  • 22 November 2024

    Since the version of the poster originally published, in the bottom right corner, the label "RAF" has been amended to "RAS" in the HTML and PDF versions.

Author information

Authors and Affiliations

  1. Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands

    Daniela S. Thommen & Daniel S. Peeper

Authors
  1. Daniela S. Thommen
    View author publications

    Search author on:PubMed Google Scholar

  2. Daniel S. Peeper
    View author publications

    Search author on:PubMed Google Scholar

Corresponding authors

Correspondence to Daniela S. Thommen or Daniel S. Peeper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thommen, D.S., Peeper, D.S. Rational combination of cancer therapies with PD1 axis blockade. Nat Rev Cancer (2024). https://doi.org/10.1038/s41568-024-00727-1

Download citation

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41568-024-00727-1

Search

Advanced search

Quick links